Aspirin Tab - 1

Phase 2Small molecule

TTaichung Veterans General Hospital

Aspirin Tab - 1 is one of 54 small molecule programs targeting Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver DiseaseRecruiting

Liver DiseasePhase 2

Recruiting

Competition

Competitive Landscape

100 competitors in Liver Disease

#DrugCompanyPhaseTrials

Kalydeco

Vertex Pharmaceuticals

Piqray

Balversa

Cibinqo

Dayvigo

Nourianz

Kyowa Kirin Co., Ltd.

Fabhalta

Rydapt

Lenvima

Opzelura

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 2Recruiting

Liver Disease

NCT06935994

Clinical

Trials by Indication[1]

Liver Disease1 trial

Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Recruiting·TTaichung Veterans General Hospital·Phase 2·NCT06935994·120 enrolled

Preeclampsia1 trial

Aspirin (ASA) Therapy and Preeclampsia Prevention

Withdrawn·UUniversity of Tennessee·Phase 4·NCT04158830

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Aspirin Tab - 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aspirin Tab - 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aspirin Tab - 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taichung Veterans General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTaichung Veterans General Hospital

Aspirin Tab - 1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Liver Disease1 trial

Preeclampsia1 trial

References

Drug Info

Quick Facts

Related News